TABLE C-1 Mercury Content from Thimerosal in the Routinely Recommended Pediatric Vaccines1 in the United States, April 2004
|
Vaccine |
Brand Name |
Manufacturer |
Hg [μg/dose] |
|
DTaP (Diphtheria and tetanus toxoids and acellular pertussis) |
Tripedia |
Aventis Pasteur, Inc. |
≤0.3 |
|
Infanrix |
Glaxo-SmithKline |
0 |
|
|
Daptacel |
Aventis Pasteur, Ltd |
0 |
|
|
Td1 (Tetanus and diphtheria toxoids) |
None |
Aventis Pasteur, Inc. |
25 |
|
Decavac |
Aventis Pasteur, Inc. |
= 0.3 |
|
|
None |
Aventis Pasteur, Ltd |
0 |
|
|
None |
Mass Public Health |
8.3 |
|
|
DTaP-Hib (Diphtheria and tetanus toxoids with acellular pertussis combined with Haemophilus influenzae type b) |
TriHIBit2 |
Aventis Pasteur |
≤0.3 |
|
Hib (Haemophilus influenzae type b) |
ActHIB/OmniHib |
Aventis Pasteur, SA |
0 |
|
HibTITER (Single dose) |
Wyeth-Lederle |
0 |
|
|
PedvaxHIB liquid |
Merck |
0 |
|
|
Hib/HepB (Haemophilus influenzae type b combined with Hepatitis B ) |
COMVAX |
Merck |
0 |
|
Hep B (Hepatitis B) (pediatric formulation) |
Engerix B |
Glaxo-SmithKline |
<0.5 |
|
Recombivax HB |
Merck |
0 |
|
|
Influenza |
Fluzone3 |
Aventis Pasteur, Inc. |
12.5 |
|
Fluzone |
Aventis Pasteur, Inc. |
≤0.5ug/ |
|
|
(Preservative Free) |
|
0.25mL dose |
|
|
Pneumococcal |
Prevnar (pneumoconjugate) |
Wyeth |
0 |
|
IPV (Inactivated polio vaccine) |
IPOL |
Aventis Pasteur, SA |
0 |
|
Poliovax |
Aventis Pasteur, Ltd. |
0 |
|
|
MMR (Measles, mumps, and rubella) |
MMR-II |
Merck |
0 |
|
Varicella |
Varivax |
Merck |
0 |
|
1Licensed for persons 7 years of age and older. 2For use in children 15 to 18 months of age. 3Influenza vaccine is recommended for children 6-23 months of age. MMWR (2004) 52:1-4; MMWR (2004) 53:1-3. |
|||
TABLE C-2 Mercury Content from Thimerosal in the Currently Licensed Vaccines That Are Recommended for Some Children in the United States, April 2004
|
Vaccine |
Brand Name |
Manufacturer |
Hg [μg/dose] |
|
DT (Diphtheria and tetanus toxoids) |
All Products |
Aventis Pasteur, Inc. (single dose) |
0.3 |
|
|
Aventis Pasteur, Inc. (multi-dose) |
25 |
|
|
|
Aventis Pasteur, Ltd* |
25 |
|
|
TT (Tetanus Toxoid) |
All Products |
Aventis Pasteur, Inc. |
25 |
|
Pneumococcal Polysaccharide |
Pneumovax 23 |
Merck |
0 |
|
Hepatitis A |
Havrix |
Glaxo-SmithKline |
0 |
|
Vaqta |
Merck |
0 |
|
|
Influenza |
Fluzone1 |
Aventis Pasteur, Inc. |
25 |
|
Fluzone (Preservative free) |
Aventis Pasteur, Inc. |
≤1 μg/0.5 mL dose or ≤0.5 μg/ 0.25 mL dose |
|
|
Fluvirin |
Evans |
25 |
|
|
Fluvirin |
Evans |
<1 μg |
|
|
Influenza, Live |
FluMist |
MedImmune |
0 |
|
*Not available in the United States. 1Children under 3 years of age received half of a vaccine dose (0.25 mL or 12.5 μg mercury/dose). |
|||
TABLE C-3 Mercury Content from Thimerosal in Other Licensed Vaccines in the United States, April 2004
|
Vaccine |
Brand Name |
Manufacturer |
Hg [μg/dose] |
|
Anthrax |
BioThrax |
BioPort Corporation |
0 |
|
Smallpox |
Dryvax |
Wyeth |
0 |
|
BCG* |
|
Organon Tecknika |
0 |
|
Mycobax |
Aventis Pasteur, Ltd |
0 |
|
|
Hepatitis A-Hepatitis B |
Twinrix |
Glaxo-SmithKline |
<1 μg |
|
Hepatitis B |
Engerix B (adult formulation) |
Glaxo-SmithKline |
< 0.5 |
|
|
Recombivax HB (adult formulation) |
Merck |
25 |
|
|
Recombivax HB (adult formulation) |
Merck |
0 |
|
Lyme* |
LYMErix |
Glaxo-SmithKline |
0 |
|
Meningococcal1 |
Menomune A, C, AC and A/C/Y/W-135 |
Aventis Pasteur, Inc. (multidose) |
25 |
|
|
Single dose |
0 |
|
|
Rabies |
IMOVAX |
Aventis Pasteur SA |
0 |
|
Rabavert |
Chiron Behring |
0 |
|
|
Typhoid Fever |
Typhim Vi |
Aventis Pasteur SA |
0 |
|
Vivotif Berna |
Berna Biotech, Ltd. |
0 |
|
|
Yellow Fever |
YF-VAX |
Aventis Pasteur, Inc. |
0 |
|
Japanese Encephalitis Vaccine |
JE-VAX |
Aventis Pasteur, Inc. |
35 |
|
*Not available in the United States. 1Menomune A/C/Y/W-135, a thimerosal-containing vaccine, is not indicated for infants and children younger than 2 years of age except as short-term protection of infants 3 months and older against Group A. (Physician’s Desk Reference, 2001). |
|||